Background Bleeding is a serious adverse effect of vitamin K antagonists (VKAs).
Anticoagulation reversal is required in some acute cases. This is usually accomplished by …

Study Objectives Patients with major bleeding on vitamin K antagonists (VKA) require rapid
reversal by supplementation with vitamin K–dependent factors (VKDFs) and intravenous VK …

Background A four-factor prothrombin complex concentrate (4F-PCC) has recently been
approved by the FDA for urgent vitamin K antagonist (VKA, eg warfarin) reversal in patients …

Prothrombin complex concentrate (PCC) is used for reversal of vitamin K antagonists (VKA)
in patients with bleeding complications. This study aims to assess benefits and harms of 4 …

Introduction. To investigate the impact of a 4‐factor prothrombin complex concentrate (4F‐
PCC [Beriplex®/Kcentra®]) versus plasma on “time to procedure” in patients with …

Objectives Early reversal of anticoagulation improves outcomes in major bleeding and
emergency surgery. To reverse vitamin K antagonists (VKA), vitamin K in addition to …

Bleeding events and life-threatening hemorrhage are the most feared complications of
warfarin therapy. Prompt anticoagulant reversal aimed at replacement of vitamin K …

Background Four-factor prothrombin complex concentrate (4F-PCC) is widely used for
urgent reversal of anticoagulation with warfarin, but the optimal 4F-PCC dosing approach is …

Introduction: The 4-factor prothrombin complex concentrates (4F-PCCs) are very effective in
urgent reversal of vitamin K antagonist (VKA) anticoagulant therapy, including correction of …

Objective: The objective of this study was to evaluate the effectiveness of 3-factor
prothrombin complex concentrate (3F-PCC) compared to 4-factor PCC (4F-PCC) in warfarin …